Magnolia Diagnostics agreed to pay federal and investor settlements totaling $24 million over allegations it billed Medicare for unnecessary respiratory panel testing tied to COVID screening in senior communities.
Magnolia Diagnostics, a Dallas clinical lab, and its owners John Bains and Kelly Bains reached a $19.2 million settlement with the United States to resolve False Claims Act allegations. Investors in Magnolia will pay an extra $4.8 million to address related common law claims and federal debt procedures, bringing combined recoveries to $24 million.
The government alleges that beginning in April 2020 Magnolia pushed expensive respiratory pathogen panel tests, or RPPs, on senior living facilities that were seeking COVID-19 screening. According to the complaints, Magnolia used prefilled requisition forms that defaulted to RPP testing and coded diagnoses before individualized medical review took place.
Prosecutors say provider signatures on those requisitions were treated as blanket or standing orders, and Magnolia relied on those as authorization to run panels across entire communities. In several instances, the complaint alleges, Magnolia performed RPPs despite provider or facility objections, and in some cases continued testing after communities explicitly requested COVID-only screening.
The United States also accuses John Bains of threatening to withhold COVID testing from communities that refused RPPs, and of altering signed requisition forms to expand the scope of authorization beyond the original facility. At least two altered forms allegedly served as the basis for panel testing at multiple facilities not covered by the original paperwork.
Magnolia is further accused of freezing thousands of respiratory specimens for weeks or months before thawing and testing them, producing RPP results long after the results could influence treatment, isolation, or infection control. The government alleges that from April 1, 2020, to Sept. 30, 2021, Magnolia, John Bains, and Kelly Bains knowingly submitted or caused submission of false claims for thousands of medically unnecessary RPPs.
“The Justice Department is committed to protecting taxpayer-funded programs and holding accountable those who exploit them,” said Assistant Attorney General Brett A. Shumate of the Justice Department’s Civil Division. “We will pursue not only companies that submit false claims and the owners who direct the misconduct, but also investors who receive and retain its financial benefits — especially when vulnerable Americans are exploited for profit.”
U.S. Attorney Ryan Raybould for the Northern District of Texas also stressed civil tools in the fight against healthcare fraud: “My office is committed to tackling healthcare fraud through the use of all available tools, both through criminal prosecutions and, as here, civil investigations. Too many of our healthcare dollars are lost to fraud, waste, and abuse, but civil settlements like this one help recover valuable healthcare dollars for the American taxpayer.”
Officials from the Department of Health and Human Services Office of Inspector General added that protecting seniors and Medicare integrity was central to the probe. “Protecting seniors and safeguarding Medicare are core to our mission,” said Acting Deputy Inspector General for Investigations Scott J. Lampert. “As alleged, Magnolia Diagnostics showed reckless disregard for medical necessity, beneficiary well-being, and the law — all to boost its profits during a national public health emergency.”
The case was developed by a coordinated team: the Justice Department’s Civil Division, Commercial Litigation Branch, Fraud Section, and the U.S. Attorney’s Office for the Northern District of Texas, alongside HHS-OIG. The matter was handled by Associate Deputy Attorney General Paul Perkins, Fraud Section Trial Attorney Asha Natarajan, and Assistant U.S. Attorney Brian Stoltz for the Northern District of Texas.
The government framed the settlements as part of broader False Claims Act enforcement aimed at recovering taxpayer dollars and deterring abuse of federal healthcare programs. Authorities say the FCA remains one of the most powerful tools to confront schemes that divert public funds away from beneficiaries and lawful providers.
The claims resolved by the settlements are allegations only, and there has been no determination of liability.
